Novo Nordisk-Catalent Deal Faces Opposition From Consumer Groups Over Competition Concerns

MT Newswires Live10-18

Novo Nordisk's (NVO) pending acquisition of Catalent (CTLT) is facing a roadblock after US consumer groups and two large labor unions urged regulators to block the deal, citing competition concerns.

In a letter to the US Federal Trade Commission on Thursday, the US Public Interest Research Group, Service Employees International Union, and other groups said the deal threatens competition in obesity drugs and other gene therapies as Novo would have the ability to prevent rival manufacturers from obtaining Catalent services, which will ultimately reduce patient access to treatments.

Novo Nordisk and Catalent did not immediately respond to MTNewswires' request for comment.

Price: 117.31, Change: -0.91, Percent Change: -0.77

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment